WL Gore & Associates reported the first European clinical use of the GORE VIABAHN Endoprosthesis with Propaten Bioactive Surface on a lower profile delivery system.

The GORE VIABAHN Device is designed to percutaneously treat peripheral artery disease by relining the native vessel and also approved for endovascular grafting of peripheral arteries.

The device enables a reduction in delivery profile to 6 Fr for 5 and 6mm devices and 7 Fr for 7 and 8mm devices and is delivered over a 0.018" or 0.014" guidewire.

The reduced delivery profile provides interventionalists with greater options for delivery with the same trackability and device performance in treating stenoses and occlusions of the Superficial Femoral Artery (SFA) and other peripheral arteries where a small access size is critical.

The new device is available with a 120 cm long delivery catheter and incorporates the CARMEDA BioActive Surface (CBAS Surface), which utilizes end-point immobilization of derivatized heparin to the luminal surface of the endoprosthesis.

The CBAS Surface technology preserves the heparin bioactive sites such that they remain free to interact with the blood at the device surface without being consumed.

The stent-graft is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure.
The flexibility of the GORE VIABAHN Endoprosthesis enables it to better traverse tortuous areas of the SFA and peripheral arteries, allowing it to conform to these arteries and withstand complex mechanical motion